Research News for October 2010
-
Fertility Counseling Before Cancer Treatment Boosts Quality of Life
Research suggests that young women who get fertility counseling before cancer treatment have fewer regrets and better overall quality of life after treatment compared to women who don't get fertility counseling.
-
Children Can Inherit Abnormal Breast Cancer Genes from Father
Research suggests that women are much more likely to be referred for genetic counseling if the family history of breast or ovarian cancer is on their mother's side rather than their father's.
-
Study Reinforces Link Between Breast Cancer Risk and Hormone Replacement Therapy
A new analysis of Women's Health Initiative data shows that women who use combination HRT are nearly twice as likely to die from breast cancer compared to women who don't use HRT.
-
Centers for Disease Control Creates New Committee to Help Young Women Learn More About Breast Health
The CDC has created a new committee to help younger women, especially women younger than 40 and women at high risk of breast cancer, learn more about breast health and breast cancer.
-
Experimental Eribulin May Help Treat Various Types of Metastatic Breast Cancer
Research suggests that the experimental medicine eribulin may be a good treatment for various types of metastatic breast cancer that have stopped responding or failed to respond to other treatments.
-
Herceptin Effectiveness Not Affected by Obesity
A small study found that Herceptin worked equally well in obese and non-obese women diagnosed with HER2-positive, metastatic breast cancer.
-
Herceptin Works Well in Older Women Diagnosed with HER2-Positive, Metastatic Disease
A small study suggests that older women diagnosed with HER2-positive, metastatic breast cancer can benefit from Herceptin treatment.
-
Experimental Iniparib Plus Chemo Can Help Treat Metastatic, Triple-Negative Disease
A small study found that iniparib -- one of several new, experimental medicines called PARP inhibitors -- improved survival when combined with chemotherapy to treat metastatic, triple-negative breast cancer.
-
Experimental T-DM1 May Help Treat Metastatic, HER2-Positive Disease
A small, early study suggests that T-DM1, an experimental medicine, may be a better first treatment for women diagnosed with metastatic, HER2-positive breast cancer than a combination of Herceptin and Taxotere.
-
Use of Computer-Aided Detection to Read Mammograms Up
Research shows that computer-aided detection (CAD) is used in most mammograms paid for by Medicare.
